A Gateway to New Medicines
In 1999, Stanford University professor Chaitan Khosla received the National Science Foundation's Alan T. Waterman Award, the nation's highest honor for young scientists and engineers 3 .
Established by Congress in 1975 to mark the 25th anniversary of the National Science Foundation and honor its first director 2 4 .
When Khosla received the award in 1999, it included a $500,000 grant over three years for scientific research or advanced study 3 .
Original Award Value (1999)
1992
Khosla joined Stanford University as an assistant professor 8 .
1990s
Ascended to become a professor in the Department of Chemical Engineering, with courtesy appointments in Chemistry and Biochemistry 6 8 .
2000s
His research group focused on studying the catalytic mechanisms and structure of enzymes used for protein synthesis 6 .
A prominent family of structurally diverse natural products that include many renowned pharmaceuticals, agrochemicals, and other commercially important compounds .
Remarkable enzymatic machines that assemble polyketides in nature 8 .
| Polyketide Drug | Therapeutic Use | Origin |
|---|---|---|
| Doxorubicin | Cancer treatment | Type II iterative PKS |
| Daunorubicin | Cancer treatment | Type II iterative PKS |
| Tetracyclines | Antibiotics | Type II PKS systems |
| Anthracyclines | Cancer treatment | Type II PKS systems |
| Component | Function | Significance |
|---|---|---|
| Polyketide Synthases (PKS) | Enzymatic assembly lines that construct polyketide structures | Fundamental machinery that Khosla engineered to produce novel compounds 8 |
| Acyl Carrier Protein (ACP) | Delivers building blocks during polyketide assembly | Key delivery system for polyketide construction |
| Malonyl-CoA | Primary extender unit for polyketide chain elongation | Essential building block for polyketide assembly |
| Type II "Minimal" PKS Systems | Simplified model systems for studying polyketide biosynthesis | Enabled fundamental insights into PKS mechanisms |
Khosla's research represented a paradigm shift in pharmaceutical development. His work enabled scientists to potentially engineer microorganisms to produce new antimicrobial agents in ways never before possible 3 .
"An exciting new approach for the production of new antimicrobial agents from engineered organisms" 3
Scientific Publications
Patents
Companies Founded
Waterman Award Year
Khosla also dedicated significant effort to understanding the molecular basis of Celiac Sprue, an autoimmune disorder of the small intestine 6 8 .
His lab identified a 33-mer peptide as the primary initiator of the inflammatory response to gluten, marking a landmark discovery in understanding this condition 8 .
The Waterman Award served as a springboard for Khosla's continued success.
Co-founded to address Celiac Sprue and related conditions.
A non-profit organization demonstrating his commitment to translating basic science into practical applications for human health 8 .
Chaitan Khosla's receipt of the Alan T. Waterman Award in 1999 recognized not just his past achievements but the tremendous potential of his research approach. His work has indeed revolutionized our understanding of nature's synthetic capabilities and opened new pathways for drug discovery.
From that early recognition of his promise, Khosla has built a remarkable career that exemplifies the type of groundbreaking science the Waterman Award was designed to foster. His research continues to bridge the gap between fundamental science and practical medical applications, demonstrating how engineering principles can be applied to biological systems to address some of humanity's most pressing health challenges.
The legacy of Khosla's Waterman Award-winning work lives on in the continued advancement of biosynthetic engineering and the ongoing development of new therapeutics inspired by his pioneering research.